Eli Lilly completed eight acquisitions worth $10 billion in 2026 to strengthen its GLP-1 pipeline after Mounjaro and Zepbound accounted for nearly two-thirds of Q1 sales and surpassed Novo Nordisk. The company halved its German manufacturing investment from €2.3 billion to €1.15 billion, cutting projected Alzey facility jobs from 1,000 to 500.
Eli Lilly has completed eight deals worth $10 billion upfront in 2026 to bolster its GLP-1 pipeline after Mounjaro and Zepbound delivered nearly two-thirds of Q1 sales and overtook Novo Nordisk as market leader. Management signals more acquisitions are planned to offset patent expirations and counter competitive threats.
The company scaled back its planned €2.3 billion Alzey, Germany manufacturing facility investment by about half to €1.15 billion, reducing projected jobs from 1,000 to 500 due to policy uncertainty over proposed healthcare reforms. Executives indicated remaining capital may be redeployed to expand US facilities in Pennsylvania to enhance domestic production.
Eli Lilly integrated Weight Watchers Med+ into its LillyDirect healthcare platform, enabling patients on GLP-1 therapies to access behavioral coaching, nutritional guidance and community support alongside prescription fulfillment. This combined clinical and lifestyle approach aims to improve patient adherence and long-term weight-management outcomes.
Fool
